Artiva Biotherapeutics (ARTV) Competitors $5.41 +0.57 (+11.78%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.20 -0.21 (-3.88%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARTV vs. MLTX, NAGE, OPT, BCYC, KROS, ARCT, KALV, ESPR, INBX, and PRTAShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include MoonLake Immunotherapeutics (MLTX), Niagen Bioscience (NAGE), Opthea (OPT), Bicycle Therapeutics (BCYC), Keros Therapeutics (KROS), Arcturus Therapeutics (ARCT), KalVista Pharmaceuticals (KALV), Esperion Therapeutics (ESPR), Inhibrx Biosciences (INBX), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Its Competitors MoonLake Immunotherapeutics Niagen Bioscience Opthea Bicycle Therapeutics Keros Therapeutics Arcturus Therapeutics KalVista Pharmaceuticals Esperion Therapeutics Inhibrx Biosciences Prothena Artiva Biotherapeutics (NASDAQ:ARTV) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership. Do analysts rate ARTV or MLTX? Artiva Biotherapeutics currently has a consensus target price of $18.25, suggesting a potential upside of 237.34%. MoonLake Immunotherapeutics has a consensus target price of $36.00, suggesting a potential upside of 278.15%. Given MoonLake Immunotherapeutics' higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Artiva Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60MoonLake Immunotherapeutics 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07 Does the media refer more to ARTV or MLTX? In the previous week, MoonLake Immunotherapeutics had 21 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 32 mentions for MoonLake Immunotherapeutics and 11 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.69 beat MoonLake Immunotherapeutics' score of 0.12 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Which has preferable valuation and earnings, ARTV or MLTX? Artiva Biotherapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$250K528.67-$65.37MN/AN/AMoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-3.42 Which has more risk & volatility, ARTV or MLTX? Artiva Biotherapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Is ARTV or MLTX more profitable? MoonLake Immunotherapeutics' return on equity of -40.98% beat Artiva Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A -42.60% -37.76% MoonLake Immunotherapeutics N/A -40.98%-35.81% Do insiders & institutionals hold more shares of ARTV or MLTX? 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryArtiva Biotherapeutics beats MoonLake Immunotherapeutics on 7 of the 12 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$118.22M$3.43B$6.23B$10.66BDividend YieldN/A2.27%5.71%4.82%P/E RatioN/A25.1230.4330.34Price / Sales528.67507.39595.82134.75Price / CashN/A45.5737.0161.44Price / Book0.7010.4012.046.60Net Income-$65.37M-$52.62M$3.32B$276.82M7 Day Performance-9.98%2.09%1.88%2.53%1 Month Performance79.73%12.32%7.68%3.71%1 Year Performance-48.28%14.12%56.01%33.82% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva Biotherapeutics3.9105 of 5 stars$5.41+11.8%$18.25+237.3%-46.8%$118.22M$250K0.0081Gap UpMLTXMoonLake Immunotherapeutics2.8943 of 5 stars$9.35+2.5%$36.00+285.0%-79.4%$585.79MN/A-3.362Trending NewsNAGENiagen Bioscience2.3224 of 5 stars$7.21-1.6%$13.42+86.1%N/A$584.59M$99.60M34.33120OPTOpthea0.4522 of 5 stars$3.41+7.2%$1.33-60.9%-18.8%$583.10M$30K0.008News CoverageGap UpHigh Trading VolumeBCYCBicycle Therapeutics3.4375 of 5 stars$8.16-0.1%$22.22+172.3%-68.2%$566.23M$35.28M-2.32240Upcoming EarningsKROSKeros Therapeutics3.0596 of 5 stars$15.19+9.8%$30.00+97.5%-74.7%$561.71M$3.55M49.00100High Trading VolumeARCTArcturus Therapeutics3.4594 of 5 stars$21.51+4.1%$50.57+135.1%-40.9%$561.02M$109.80M-9.65180Trending NewsAnalyst DowngradeKALVKalVista Pharmaceuticals3.8146 of 5 stars$11.54+4.0%$26.43+129.0%-7.8%$560.81MN/A-2.93100ESPREsperion Therapeutics3.734 of 5 stars$2.82+2.5%$7.00+148.2%+31.6%$554.46M$332.31M-5.76200INBXInhibrx Biosciences2.0544 of 5 stars$38.22+2.6%N/A+272.7%$539.58M$200K-3.61166Trending NewsGap UpPRTAProthena2.693 of 5 stars$10.37+4.5%$20.50+97.7%-39.6%$533.99M$10.34M-1.84130Positive News Related Companies and Tools Related Companies MLTX Alternatives NAGE Alternatives OPT Alternatives BCYC Alternatives KROS Alternatives ARCT Alternatives KALV Alternatives ESPR Alternatives INBX Alternatives PRTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTV Stock Alerts